The International Team for Implantology (ITI) has announced the appointment of Dr Friedrich Buck to the position of Executive Director, effective February 1, 2009.
Dr Buck comes to the ITI from Ivoclar Vivadent. With a graduate degree and doctorate in dentistry from the University of Ulm, Germany, Dr Buck began his career in general practice in 1991. He then joined Ivocar Vivadent in 1993, where he rose to the position of Marketing Director Worldwide for clinical products in 2001.
In his new position as Executive Director of the ITI, Dr Buck's main task will be to assure the smooth organization and administration of all ITI activities in order to support the implementation of the objectives, philosophy, policy and procedures of the ITI. He will also oversee the management of the ITI Center, the administrative headquarters of the ITI in Basel, Switzerland.
"During the last few years, the ITI has evolved to become a leading academic authority in the field of implant dentistry with its more than 6,000 members from over 90 countries," said Professor Dr Dieter Weingart, President of the ITI. "As a dentist by education, who brings a wealth of experience in marketing and business administration in a globally operating enterprise, Dr Buck is an ideal choice for the position of Executive Director of the ITI."
Dr Buck takes over from Rolf Hafner, who oversaw the ITI's administration for the past six years.
About the ITI
The International Team for Implantology (ITI) unites professionals around the world from every field of implant dentistry and dental tissue regeneration. As an independent academic association, it actively promotes networking and exchange among its membership. ITI Fellows and Members regularly share their knowledge and expertise from research and clinical practice at meetings, courses and congresses with the objective of constantly improving treatment methods and outcomes to the benefit of their patients.
The ITI is active in three principal areas: research, development and education. In more than 28 years, the ITI has built a reputation for scientific rigor combined with concern for patients.
Monday, 14 October, 2024